Summary
7.02 0.12(1.74%)02/10/2026
Aptevo Therapeutics Inc. (APVO)
APVO reported last earnings on 2025-11-06 after the market. An EPS of $-40.11 was observed compared to an estimated EPS of $-37.59, resulting in a surprise value of $-2.52. A revenue of $0 million was observed compared to an estimated revenue of $0 million, resulting in a surprise value of $0 Million.
Aptevo Therapeutics Inc. (APVO)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| 1.74 | -10.39 | -21.03 | -47.65 | -73.07 | -99.04 | -100.00 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | B- |
| Recommended Rating | Sell |
| DCF | Strong Buy |
| ROE | Strong Sell |
| ROA | Strong Sell |
| Debt/Equity | Sell |
| P/E | Strong Sell |
| P/B | Buy |
Earnings
| Trading Data | ||
| Close | 7.02 | |
| Open | 7.00 | |
| High | 7.11 | |
| Low | 6.69 | |
| Volume | 21,394 | |
| Change | 0.12 | |
| Change % | 1.74 | |
| Avg Volume (20 Days) | 1,042,045 | |
| Volume/Avg Volume (20 Days) Ratio | 0.02 | |
| 52 Week Range | 0.91 - 109.80 | |
| Price vs 52 Week High | -93.61% | |
| Price vs 52 Week Low | 671.43% | |
| Range | -9.52 | |
| Gap Up/Down | -0.05 | |
Profitibility | ||
| Market Capitalization (Mln) | 8 | |
| Revenue per share | 0.0000 | |
| Net Income per share | -117.6860 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | -0.0593 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
02/03 08:05 EST - accessnewswire.com
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
Clinical progress, pipeline expansion, and operational momentum underpin leadership continuity as the Company advances into 2026 and beyond SEATTLE, WA / ACCESS Newswire / February 3, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel...
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
Clinical progress, pipeline expansion, and operational momentum underpin leadership continuity as the Company advances into 2026 and beyond SEATTLE, WA / ACCESS Newswire / February 3, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel...
01/14 03:52 EST - defenseworld.net
Short Interest in Aptevo Therapeutics Inc. (NASDAQ:APVO) Drops By 86.5%
Aptevo Therapeutics Inc. (NASDAQ: APVO - Get Free Report) was the recipient of a large decline in short interest in the month of December. As of December 31st, there was short interest totaling 139,996 shares, a decline of 86.5% from the December 15th total of 1,033,317 shares. Approximately 15.0%...
Short Interest in Aptevo Therapeutics Inc. (NASDAQ:APVO) Drops By 86.5%
Aptevo Therapeutics Inc. (NASDAQ: APVO - Get Free Report) was the recipient of a large decline in short interest in the month of December. As of December 31st, there was short interest totaling 139,996 shares, a decline of 86.5% from the December 15th total of 1,033,317 shares. Approximately 15.0%...
01/09 08:05 EST - accessnewswire.com
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
Together with cash on hand, the fully leveraged facility extends Aptevo's funding runway into 2029, enabling achievement of key clinical and preclinical milestones SEATTLE, WA / ACCESS Newswire / January 9, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology Company...
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
Together with cash on hand, the fully leveraged facility extends Aptevo's funding runway into 2029, enabling achievement of key clinical and preclinical milestones SEATTLE, WA / ACCESS Newswire / January 9, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology Company...
12/26 10:24 EST - feeds.benzinga.com
What's Going On With Aptevo Therapeutics Stock Today?
Shares of Aptevo Therapeutics Inc. (NASDAQ: APVO) are trading lower Friday after the Seattle-based company announced a one-for-eighteen reverse stock split.
What's Going On With Aptevo Therapeutics Stock Today?
Shares of Aptevo Therapeutics Inc. (NASDAQ: APVO) are trading lower Friday after the Seattle-based company announced a one-for-eighteen reverse stock split.
12/26 08:05 EST - accessnewswire.com
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split
SEATTLE, WA / ACCESS Newswire / December 26, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that it will...
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split
SEATTLE, WA / ACCESS Newswire / December 26, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that it will...
12/20 03:30 EST - defenseworld.net
Critical Contrast: Aptevo Therapeutics (NASDAQ:APVO) vs. Neumora Therapeutics (NASDAQ:NMRA)
Neumora Therapeutics (NASDAQ: NMRA - Get Free Report) and Aptevo Therapeutics (NASDAQ: APVO - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings,...
Critical Contrast: Aptevo Therapeutics (NASDAQ:APVO) vs. Neumora Therapeutics (NASDAQ:NMRA)
Neumora Therapeutics (NASDAQ: NMRA - Get Free Report) and Aptevo Therapeutics (NASDAQ: APVO - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings,...
12/09 08:05 EST - accessnewswire.com
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
100% of patients in Cohorts 1-3 remain free of cytokine release syndrome CRIS-7-derived CD3 design underpins a controlled T-cell response, supporting the differentiated safety profile, combinability with standard of care SEATTLE, WA / ACCESS Newswire / December 9, 2025 / Aptevo Therapeutics Inc....
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
100% of patients in Cohorts 1-3 remain free of cytokine release syndrome CRIS-7-derived CD3 design underpins a controlled T-cell response, supporting the differentiated safety profile, combinability with standard of care SEATTLE, WA / ACCESS Newswire / December 9, 2025 / Aptevo Therapeutics Inc....
11/19 10:57 EST - zacks.com
Aptevo Therapeutics (APVO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Aptevo Therapeutics (APVO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for...
Aptevo Therapeutics (APVO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Aptevo Therapeutics (APVO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for...
11/10 08:05 EST - accessnewswire.com
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors
First data on Aptevo's new molecule presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting SEATTLE, WASHINGTON / ACCESS Newswire / November 10, 2025 / Aptevo Therapeutics ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company advancing differentiated...
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors
First data on Aptevo's new molecule presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting SEATTLE, WASHINGTON / ACCESS Newswire / November 10, 2025 / Aptevo Therapeutics ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company advancing differentiated...
11/06 08:05 EST - accessnewswire.com
Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update
89% of evaluable mipletamig patients achieve remission in combination therapy for frontline AML across two trials Introduces first trispecific molecules, APVO451 and APVO452, advancing therapies designed to overcome immune suppression in certain solid tumors Both molecules leverage Aptevo's unique...
Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update
89% of evaluable mipletamig patients achieve remission in combination therapy for frontline AML across two trials Introduces first trispecific molecules, APVO451 and APVO452, advancing therapies designed to overcome immune suppression in certain solid tumors Both molecules leverage Aptevo's unique...
10/08 08:20 EST - accessnewswire.com
Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter
SEATTLE, WASHINGTON / ACCESS Newswire / October 8, 2025 / Aptevo Therapeutics ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel bispecific and trispecific immuno-oncology therapeutics, today announced its participation in upcoming key financial,...
Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter
SEATTLE, WASHINGTON / ACCESS Newswire / October 8, 2025 / Aptevo Therapeutics ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel bispecific and trispecific immuno-oncology therapeutics, today announced its participation in upcoming key financial,...
09/16 12:21 EST - proactiveinvestors.com
Aptevo Therapeutics shares spike on promising trial results for leukemia therapy
Aptevo Therapeutics (NASDAQ:APVO) saw its shares jump sharply after the company reported encouraging clinical data from its Phase 1b/2 RAINIER trial evaluating mipletamig, a first-in-class CD123 x CD3 bispecific antibody, in patients with newly diagnosed acute myeloid leukemia (AML) who are unfit...
Aptevo Therapeutics shares spike on promising trial results for leukemia therapy
Aptevo Therapeutics (NASDAQ:APVO) saw its shares jump sharply after the company reported encouraging clinical data from its Phase 1b/2 RAINIER trial evaluating mipletamig, a first-in-class CD123 x CD3 bispecific antibody, in patients with newly diagnosed acute myeloid leukemia (AML) who are unfit...
09/16 08:30 EST - accessnewswire.com
Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML
No dose-limiting toxicities or cytokine release syndrome observed in RAINIER to date; mipletamig shows consistently favorable safety and tolerability Trial progressing efficiently, Cohort 4 open for enrollment SEATTLE, WA / ACCESS Newswire / September 16, 2025 / Aptevo Therapeutics ("Aptevo" or...
Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML
No dose-limiting toxicities or cytokine release syndrome observed in RAINIER to date; mipletamig shows consistently favorable safety and tolerability Trial progressing efficiently, Cohort 4 open for enrollment SEATTLE, WA / ACCESS Newswire / September 16, 2025 / Aptevo Therapeutics ("Aptevo" or...
09/04 08:45 EST - accessnewswire.com
Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules
New candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEXTM design to target prostate and multiple solid tumor cancers by simultaneously engaging tumor antigens, T cells, and immunosuppressive cells Mipletamig-driven clinical validation of the CRIS-7-derived CD3 binding domain underpins...
Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules
New candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEXTM design to target prostate and multiple solid tumor cancers by simultaneously engaging tumor antigens, T cells, and immunosuppressive cells Mipletamig-driven clinical validation of the CRIS-7-derived CD3 binding domain underpins...
08/13 08:05 EST - accessnewswire.com
Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer. Engineered for precision T-cell activation in prostate cancer; part of Aptevo's growing CRIS-7-derived CD3 portfolio targeting both hematologic and solid tumors SEATTLE, WA / ACCESS Newswire...
Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer. Engineered for precision T-cell activation in prostate cancer; part of Aptevo's growing CRIS-7-derived CD3 portfolio targeting both hematologic and solid tumors SEATTLE, WA / ACCESS Newswire...
08/11 08:05 EST - accessnewswire.com
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update
Mipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4 x CD3 bispecific for multiple solid tumor types CD3 bispecific portfolio now includes three candidates - mipletamig (AML), APVO442 (prostate...
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update
Mipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4 x CD3 bispecific for multiple solid tumor types CD3 bispecific portfolio now includes three candidates - mipletamig (AML), APVO442 (prostate...
06/20 11:30 EST - accessnewswire.com
Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules
SEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing...
Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules
SEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing...
06/20 08:55 EST - accessnewswire.com
Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers
Mipletamig-driven clinical validation of the CRIS-7 derived CD3-binding domain underpins Aptevo's expansion from hematologic to solid tumors New candidate APVO455 targets Nectin-4+ cancers, joins mipletamig (AML) and APVO442 (prostate) in Aptevo's tumor-directed CD3 suite SEATTLE, WASHINGTON /...
Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers
Mipletamig-driven clinical validation of the CRIS-7 derived CD3-binding domain underpins Aptevo's expansion from hematologic to solid tumors New candidate APVO455 targets Nectin-4+ cancers, joins mipletamig (AML) and APVO442 (prostate) in Aptevo's tumor-directed CD3 suite SEATTLE, WASHINGTON /...
06/20 08:01 EST - benzinga.com
Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% on Friday.
Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% on Friday.
06/18 13:34 EST - marketwatch.com
Aptevo More Than Doubles After Favorable Results in Leukemia Study
Aptevo Therapeutics shares bounced back from Tuesday's 52-week low, more than doubling Wednesday after the company reported favorable results for its lead drug candidate in an acute myeloid leukemia study.
Aptevo More Than Doubles After Favorable Results in Leukemia Study
Aptevo Therapeutics shares bounced back from Tuesday's 52-week low, more than doubling Wednesday after the company reported favorable results for its lead drug candidate in an acute myeloid leukemia study.
Market News
×
Loading news…